These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 35160082)

  • 1. Risk of Acute Anterior Uveitis in Ankylosing Spondylitis According to the Type of Tumor Necrosis Factor-Alpha Inhibitor and History of Uveitis: A Nationwide Population-Based Study.
    Ahn SM; Kim M; Kim YJ; Lee Y; Kim YG
    J Clin Med; 2022 Jan; 11(3):. PubMed ID: 35160082
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The Effect of Tumor Necrosis Factor-Alpha Inhibitors on Uveitis in Patients with Ankylosing Spondylitis.
    Lee S; Park YJ; Lee JY
    J Korean Med Sci; 2019 Nov; 34(42):e278. PubMed ID: 31674159
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparative risk of incident and recurrent acute anterior uveitis across different biological agents in patients with ankylosing spondylitis.
    Kwon OC; Lee HS; Yang J; Park MC
    Rheumatology (Oxford); 2024 Jan; ():. PubMed ID: 38243710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Comparing the risk of developing uveitis in patients initiating anti-tumor necrosis factor therapy for ankylosing spondylitis: an analysis of a large US claims database.
    Wendling D; Joshi A; Reilly P; Jalundhwala YJ; Mittal M; Bao Y
    Curr Med Res Opin; 2014 Dec; 30(12):2515-21. PubMed ID: 25252590
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Predictors of extra-articular manifestations in axial spondyloarthritis and their influence on TNF-inhibitor prescribing patterns: results from the British Society for Rheumatology Biologics Register in Ankylosing Spondylitis.
    Derakhshan MH; Dean L; Jones GT; Siebert S; Gaffney K
    RMD Open; 2020 Jul; 6(2):. PubMed ID: 32641447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Reduced Occurrence Rate of Acute Anterior Uveitis in Ankylosing Spondylitis Treated with Golimumab - The GO-EASY Study.
    van Bentum RE; Heslinga SC; Nurmohamed MT; Gerards AH; Griep EN; Koehorst CBJM; Kok MR; Schilder AM; Verhoef M; van der Horst-Bruinsma IE
    J Rheumatol; 2019 Feb; 46(2):153-159. PubMed ID: 30385705
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Different roles of TNF inhibitors in acute anterior uveitis associated with ankylosing spondylitis: state of the art.
    Fabiani C; Vitale A; Lopalco G; Iannone F; Frediani B; Cantarini L
    Clin Rheumatol; 2016 Nov; 35(11):2631-2638. PubMed ID: 27686662
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advances in the treatment of uveitis in patients with spondyloarthritis - is it the time for biologic therapy?
    Mitulescu TC; Trandafir M; Dimăncescu MG; Ciuluvică RC; Popescu V; Predețeanu D; Istrate S; Voinea LM
    Rom J Ophthalmol; 2018; 62(2):114-122. PubMed ID: 30206554
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The risk factors and incidence of major infectious diseases in patients with ankylosing spondylitis receiving tumor necrosis factor inhibitors.
    Koo BS; Lim YC; Lee MY; Jeon JY; Yoo HJ; Oh IS; Shin JY; Kim TH
    Mod Rheumatol; 2021 Nov; 31(6):1192-1201. PubMed ID: 33494621
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The effect of extra-articular manifestations on tumor necrosis factor-α inhibitor treatment duration in patients with ankylosing spondylitis: nationwide data from the Korean College of Rheumatology BIOlogics (KOBIO) registry.
    Kim Y; Park S; Kim HS
    Clin Rheumatol; 2018 Dec; 37(12):3275-3284. PubMed ID: 30251059
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical and economic burden of extra-articular manifestations in ankylosing spondylitis patients treated with anti-tumor necrosis factor agents.
    Gao X; Wendling D; Botteman MF; Carter JA; Rao S; Cifaldi M
    J Med Econ; 2012; 15(6):1054-63. PubMed ID: 22563743
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Uveitis occurrence in patients with ankylosing spondylitis according to the type of tumour necrosis factor inhibitor: a cohort study of 175 patients.
    Choi EY; Lee M; Lee CS
    Clin Exp Rheumatol; 2020; 38(6):1132-1137. PubMed ID: 32828140
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Risk of Major Adverse Cardiovascular Events in Ankylosing Spondylitis Patients With a History of Acute Anterior Uveitis: A Nationwide, Population Based Cohort Study.
    Bai YC; Liu CH; Leong PY; Lai KL; Chen HH; Wei JC
    Front Med (Lausanne); 2022; 9():884800. PubMed ID: 35872802
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dose Reduction of Tumor Necrosis Factor Inhibitor and its Effect on Medical Costs for Patients with Ankylosing Spondylitis.
    Koo BS; Lim YC; Lee MY; Jeon JY; Yoo HJ; Oh IS; Shin JY; Kim TH
    Rheumatol Ther; 2021 Mar; 8(1):347-359. PubMed ID: 33420967
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Acute Anterior Uveitis as a Risk Factor of Ankylosing Spondylitis-A National Population-Based Study.
    Yen JC; Hsu CA; Hsiao SH; Hsu MH
    Int J Environ Res Public Health; 2017 Jan; 14(1):. PubMed ID: 28124984
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adalimumab, etanercept and infliximab for the treatment of ankylosing spondylitis: a systematic review and economic evaluation.
    McLeod C; Bagust A; Boland A; Dagenais P; Dickson R; Dundar Y; Hill RA; Jones A; Mujica Mota R; Walley T
    Health Technol Assess; 2007 Aug; 11(28):1-158, iii-iv. PubMed ID: 17651658
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Golimumab for the treatment of ankylosing spondylitis: a NICE single technology appraisal.
    Armstrong N; Joore M; van Asselt T; Misso K; Manning N; Tomini F; Kleijnen J; Riemsma R
    Pharmacoeconomics; 2013 May; 31(5):415-25. PubMed ID: 23580355
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Do tumor necrosis factor inhibitors cause uveitis? A registry-based study.
    Lim LL; Fraunfelder FW; Rosenbaum JT
    Arthritis Rheum; 2007 Oct; 56(10):3248-52. PubMed ID: 17907169
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of Incidence or Recurrence of Anterior Uveitis in Patients with Ankylosing Spondylitis Treated with Tumor Necrosis Factor Inhibitors.
    Kwon HY; Kim YJ; Kim TH; Ahn SJ
    J Clin Med; 2024 Feb; 13(3):. PubMed ID: 38337605
    [No Abstract]   [Full Text] [Related]  

  • 20. Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register.
    Lie E; Lindström U; Zverkova-Sandström T; Olsen IC; Forsblad-d'Elia H; Askling J; Kapetanovic MC; Kristensen LE; Jacobsson LTH
    Ann Rheum Dis; 2017 Sep; 76(9):1515-1521. PubMed ID: 28254789
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.